作者
Loni Perrenoud, Nicholas T Kruse, Emily Andrews, Zhiying You, Michel Chonchol, Chaorong Wu, Patrick Ten Eyck, Diana Zepeda-Orozco, Diana Jalal
发表日期
2020/3/1
期刊
Kidney medicine
卷号
2
期号
2
页码范围
155-161
出版商
Elsevier
简介
Rationale & Objective
Hyperuricemia is associated with chronic kidney disease (CKD) progression. We evaluated whether lowering serum uric acid levels improves levels of biomarkers of kidney damage.
Study Design
Post hoc analysis of clinical trial participants.
Setting & Participants
A double-blind randomized placebo-controlled study designed to lower serum uric acid levels. 80 patients with stage 3 CKD and asymptomatic hyperuricemia were randomly assigned to allopurinol treatment or placebo (300 mg/d) for 12 weeks.
Exposure/Predictor
Allopurinol treatment versus placebo.
Outcomes & Measures
We evaluated the change from baseline for the following urinary biomarkers of kidney damage: albumin-creatinine ratio (ACR), neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule 1 (KIM-1), and transforming growth factor β1 (TGF-β1). Additionally, we evaluated CKD Epidemiology Collaboration …
学术搜索中的文章
L Perrenoud, NT Kruse, E Andrews, Z You, M Chonchol… - Kidney medicine, 2020